MCL1
Induced myeloid leukemia cell differentiation protein Mcl-1
As of the edition of 20 October 2026, MCL1 (induced myeloid leukemia cell differentiation protein Mcl-1, UniProt Q07820) has 6 drugs tested at it and 7 companies on the list, 7 on route A and 0 on route B.
Sources: UniProt, ClinicalTrials.gov, ChEMBL, FDA Orange Book and Purple Book, Pharos.
The protein
- UniProt
- Q07820
- How well studied
- Chemical tools exist; no approved drug acts on it
- Where it sits in the cell
- In more than one place
- Solved structures
- 147
- Disease areas
- Cancer; Blood and lymph; Immune system; Heart and blood vessels; Lungs and airways; Skin and connective tissue; Digestive system; Infections
- Registered trials of its drugs
- 29
Drugs at this target
| Status | Count |
|---|---|
| Stopped | 6 |
| Total | 6 |
| Drug | Status | Furthest phase | US protection |
|---|---|---|---|
| Obatoclax | Stopped | Phase 3 | none listed |
| PRT1419 | Stopped | Phase 1 | none listed |
| Tapotoclax | Stopped | Phase 1 | none listed |
| AZD-5991 | Stopped | Phase 3 | none listed |
| ABBV-467 | Stopped | Phase 1 | none listed |
| Murizatoclax | Stopped | Phase 1 | none listed |
6 of 6 drugs, the most tested first.
Companies at this target
| Where the company stands | Companies |
|---|---|
| Route A | 7 |
| Total on the list | 7 |
| Company | Route |
|---|---|
| Amgen | Route A |
| AbbVie | Route A |
| AstraZeneca | Route A |
The other 4 companies at MCL1
In the product7 companies in all; 4 are not named here, and no score is.
See the 7 companies at MCL1, ranked, with the facts behind eachRequest access. Nothing is shown until you do.